Targeting Androgen Receptor in Breast Cancer: Enzalutamide as a Novel Breast Cancer Therapeutic
Abstract
In breast cancers, the androgen receptor (AR) is more widely expressed than estrogen receptor alpha (ER) or the progesterone receptor (PR) (1), which are used as therapeutic targets and biomarkers, suggesting a potential role for AR in BC. To explore the function of AR in models of the three main subtypes of breast cancer (ER positive, ER negative and Her2 ), we are using anew-generation AR inhibitor, enzalutamide, which impairs nuclear localization of AR. This is a very different mode of action than previous generation anti-androgens such as bicalutamide (Casodex), which is a competitive inhibitor of endogenous androgens that allows ligand-mediated nuclear localization of AR. Enzalutamide has shown success in the clinic in patients with late stage prostate cancer. The research in this proposal generates preclinical data testing whether inhibition of AR with enzalutamide will be effective in breast cancer and utilize preclinical models of the three main subtypes of breast cancer. Our goal is to determine if and how enzalutamide should be combined with currently used standard of care treatments in the three main types of breast cancer, with the primary objectives of the research being to guide the design of future clinical trials with enzalutamide.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2016
- Accession Number
- AD1032760
Entities
People
- Jennifer K Richer
Organizations
- University of Colorado Boulder